Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100µg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma

NCT01585649 is registered in ClinicalTrials.gov with Merckle GmbH as lead sponsor.

NCT NCT01585649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01585649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100µg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma
Lead sponsor
Merckle GmbH
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2012
Completion date
April 30, 2015
Enrollment
21 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

ewing family of tumors, rhabdomyosarcoma